These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 34292396)

  • 1. Risk of multiple sclerosis relapses when switching from fingolimod to cell-depleting agents: the role of washout duration.
    Ferraro D; Iaffaldano P; Guerra T; Inglese M; Capobianco M; Brescia Morra V; Zaffaroni M; Mirabella M; Lus G; Patti F; Cavalla P; Cellerino M; Malucchi S; Pisano E; Vitetta F; Paolicelli D; Sola P; Trojano M;
    J Neurol; 2022 Mar; 269(3):1463-1469. PubMed ID: 34292396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequency and risk factors of rebound after fingolimod discontinuation - A retrospective study.
    Maunula A; Atula S; Laakso SM; Tienari PJ
    Mult Scler Relat Disord; 2024 Jan; 81():105134. PubMed ID: 37980790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis.
    Havla J; Tackenberg B; Hellwig K; Meinl I; Krumbholz M; Seitz F; Eienbröker C; Gold R; Hohlfeld R; Kleiter I; Kümpfel T
    J Neurol; 2013 May; 260(5):1382-7. PubMed ID: 23266894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis.
    Zhu C; Zhou Z; Roos I; Merlo D; Kalincik T; Ozakbas S; Skibina O; Kuhle J; Hodgkinson S; Boz C; Alroughani R; Lechner-Scott J; Barnett M; Izquierdo G; Prat A; Horakova D; Kubala Havrdova E; Macdonell R; Patti F; Khoury SJ; Slee M; Karabudak R; Onofrj M; Van Pesch V; Prevost J; Monif M; Jokubaitis V; van der Walt A; Butzkueven H;
    J Neurol Neurosurg Psychiatry; 2022 Dec; 93(12):1330-1337. PubMed ID: 36261289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disease Reactivation after Fingolimod Discontinuation in Pregnant Multiple Sclerosis Patients.
    Bianco A; Lucchini M; Totaro R; Fantozzi R; De Luca G; Di Lemme S; Presicce G; Evangelista L; Di Tommaso V; Pastorino R; De Fino C; De Arcangelis V; Centonze D; Mirabella M
    Neurotherapeutics; 2021 Oct; 18(4):2598-2607. PubMed ID: 34494237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes after fingolimod to alemtuzumab treatment shift in relapsing-remitting MS patients: a multicentre cohort study.
    Frau J; Saccà F; Signori A; Baroncini D; Fenu G; Annovazzi P; Capobianco M; Signoriello E; Laroni A; La Gioia S; Sartori A; Maniscalco GT; Bonavita S; Clerico M; Russo CV; Gallo A; Lapucci C; Carotenuto A; Sormani MP; Cocco E;
    J Neurol; 2019 Oct; 266(10):2440-2446. PubMed ID: 31209573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod Treatment.
    Hatcher SE; Waubant E; Nourbakhsh B; Crabtree-Hartman E; Graves JS
    JAMA Neurol; 2016 Jul; 73(7):790-4. PubMed ID: 27135594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical effectiveness of reduced fingolimod dose in relapsing remitting multiple sclerosis-a Portuguese cohort.
    Ramos-Lopes J; Batista S; Barradas P; Campelo I; Correia I; Nunes C; Macário C; Sousa L
    Neurol Sci; 2021 Mar; 42(3):1039-1043. PubMed ID: 32719903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors for multiple sclerosis relapses after switching from natalizumab to fingolimod.
    Hoepner R; Havla J; Eienbröker C; Tackenberg B; Hellwig K; Meinl I; Hohlfeld R; Gold R; Kümpfel T; Kleiter I
    Mult Scler; 2014 Nov; 20(13):1714-20. PubMed ID: 24842961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US.
    Ontaneda D; Nicholas J; Carraro M; Zhou J; Hou Q; Babb J; Riester K; Mendoza JP; Livingston T; Jhaveri M
    Mult Scler Relat Disord; 2019 Jan; 27():101-111. PubMed ID: 30368221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benefit-risk Assessment of Cladribine Using Multi-criteria Decision Analysis (MCDA) for Patients With Relapsing-remitting Multiple Sclerosis.
    Vermersch P; Martinelli V; Pfleger C; Rieckmann P; Alonso-Magdalena L; Galazka A; Dangond F; Phillips L
    Clin Ther; 2019 Feb; 41(2):249-260.e18. PubMed ID: 30846120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative discontinuation, effectiveness, and switching practices of dimethyl fumarate and fingolimod at 36-month follow-up.
    Vollmer B; Ontaneda D; Harris H; Nair K; Bermel RA; Corboy JR; Fox RJ; Vollmer T; Cohen JA; Alvarez E; Hersh CM
    J Neurol Sci; 2019 Dec; 407():116498. PubMed ID: 31644992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 12-month follow-up.
    Hersh CM; Love TE; Cohn S; Hara-Cleaver C; Bermel RA; Fox RJ; Cohen JA; Ontaneda D
    Mult Scler Relat Disord; 2016 Nov; 10():44-52. PubMed ID: 27919497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurological update: treatment escalation in multiple sclerosis patients refractory to fingolimod-potentials and risks of subsequent highly active agents.
    Korsen M; Pfeuffer S; Rolfes L; Meuth SG; Hartung HP
    J Neurol; 2022 May; 269(5):2806-2818. PubMed ID: 34999925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of multiple sclerosis outcomes when switching to ocrelizumab.
    Zhong M; van der Walt A; Stankovich J; Kalincik T; Buzzard K; Skibina O; Boz C; Hodgkinson S; Slee M; Lechner-Scott J; Macdonell R; Prevost J; Kuhle J; Laureys G; Van Hijfte L; Alroughani R; Kermode AG; Butler E; Barnett M; Eichau S; van Pesch V; Grammond P; McCombe P; Karabudak R; Duquette P; Girard M; Taylor B; Yeh W; Monif M; Gresle M; Butzkueven H; Jokubaitis VG
    Mult Scler; 2022 May; 28(6):958-969. PubMed ID: 34623947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Half-dose fingolimod for treating relapsing-remitting multiple sclerosis: Observational study.
    Zecca C; Merlini A; Disanto G; Rodegher M; Panicari L; Romeo MAL; Candrian U; Messina MJ; Pravatà E; Moiola L; Stefanin C; Ghezzi A; Perrone P; Patti F; Comi G; Gobbi C; Martinelli V
    Mult Scler; 2018 Feb; 24(2):167-174. PubMed ID: 28273776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How to switch disease-modifying treatments in multiple sclerosis: Guidelines from the French Multiple Sclerosis Society (SFSEP).
    Bigaut K; Cohen M; Durand-Dubief F; Maillart E; Planque E; Zephir H; Lebrun-Frenay C; de Seze J;
    Mult Scler Relat Disord; 2021 Aug; 53():103076. PubMed ID: 34161898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switch from sequestering to anti-CD20 depleting treatment: disease activity outcomes during wash-out and in the first 6 months of ocrelizumab therapy.
    Signoriello E; Lus G; Bonavita S; Lanzillo R; Saccà F; Landi D; Frau J; Baroncini D; Zaffaroni M; Maniscalco GT; Curti E; Sartori A; Cepparulo S; Marfia GA; Nicoletti CG; Carotenuto A; Nociti V; Caleri F; Sormani MP; Signori A
    Mult Scler; 2022 Jan; 28(1):93-101. PubMed ID: 33855897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alemtuzumab as rescue therapy in a cohort of 50 relapsing-remitting MS patients with breakthrough disease on fingolimod: a multi-center observational study.
    Huhn K; Bayas A; Doerck S; Frank B; Gerbershagen K; Hellwig K; Kallmann B; Kleinschnitz C; Kleiter I; Lee DH; Limmroth V; Mäurer M; Meuth S; Rieckmann P; Ruck T; Gold R; Linker RA
    J Neurol; 2018 Jul; 265(7):1521-1527. PubMed ID: 29696498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transitioning From S1P Receptor Modulators to B Cell-Depleting Therapies in Multiple Sclerosis: Clinical, Radiographic, and Laboratory Data.
    Rowles WM; Hsu WY; McPolin K; Li A; Merrill S; Guo CY; Green AJ; Gelfand JM; Bove RM
    Neurol Neuroimmunol Neuroinflamm; 2022 Jul; 9(4):. PubMed ID: 35581005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.